4d Molecular Therapeutics, Inc.

Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
www.4dmoleculartherapeutics.com

Moat Score

Market Cap $142.42M
PE -1
Debt -
Cash $149.34M
EV -
FCF -$138.37M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$160.87M
EBIT	-$187.84M
ROE	-32%
ROA	-34%
FCF	-$138.37M
Equity	$510.61M
Growth Stability	1
PE	-0.89
PB	0.28
P/FCF	-1.03
P/S	3.85K
Price/Cash	1.05
Net Margins	-435K%
Op. Margins	-508K%
Sales Growth YoY	-105%
Sales Growth QoQ	-67%
Sales CAGR	-59%
Equity CAGR	24%
Earnings Growth YoY	54%

Earnings Growth QoQ	13%
Sales CAGR 5Y	-59%
Equity CAGR 5Y	24%
Earnings CAGR 3Y	-67%
Sales CAGR 3Y	-67%
Equity CAGR 3Y	40%
Market Cap	$142.42M
Revenue	$37.00K
Assets	$560.38M
Cash	$149.34M
Shares Outstanding	45.79M
Moat Score	1%
Working Capital	405.78M
Current Ratio	14.92
Shares Growth 3y	22%
Equity Growth QoQ	-8%
Equity Growth YoY	66%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease.

SEC Filings

Direct access to 4d Molecular Therapeutics, Inc. (FDMT) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does 4d Molecular Therapeutics, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of 4d Molecular Therapeutics, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

4d Molecular Therapeutics, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for 4d Molecular Therapeutics, Inc..

Years

Calculation mode

= -$1.4B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$138M	-$138M	-$138M	-$138M	-$138M	-$138M	-$138M	-$138M	-$138M	-$138M	-$138M	-$1.4B
DCF		-$126M	-$114M	-$104M	-$95M	-$86M	-$78M	-$71M	-$65M	-$59M	-$53M	-$533M
Value	-$1.4B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	-706%	-416%	-395%	-3K%	-487%	-435K%	-435K%
ROA	-	-20%	-20%	-42%	-33%	-34%	-34%
ROE	-	-22%	-22%	-46%	-33%	-32%	-32%

Bad Net Margins (-434.78K%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	95%	33%	-83%	562%	-100%	-59%
Earnings YoY growth	-	15%	26%	51%	-6%	60%	-
Equity YoY growth	-	-451%	24%	-28%	33%	66%	24%
FCF YoY growth	-	30%	51%	26%	-20%	76%	-